Shoskes D A, Zeitlin S I, Shahed A, Rajfer J
Institute for Male Urology, Encino, California, USA.
Urology. 1999 Dec;54(6):960-3. doi: 10.1016/s0090-4295(99)00358-1.
The National Institutes of Health (NIH) category III chronic prostatitis syndromes (nonbacterial chronic prostatitis and prostatodynia) are common disorders with few effective therapies. Bioflavonoids have recently been shown in an open-label study to improve the symptoms of these disorders in a significant proportion of men. The aim of this study was to confirm these findings in a prospective randomized, double-blind, placebo-controlled trial.
Thirty men with category IIIa and IIIb chronic pelvic pain syndrome were randomized in a double-blind fashion to receive either placebo or the bioflavonoid quercetin 500 mg twice daily for 1 month. The NIH chronic prostatitis symptom score was used to grade symptoms and the quality-of-life impact at the start and conclusion of the study. In a follow-up unblind, open-label study, 17 additional men received 1 month of a supplement containing quercetin, as well as bromelain and papain (Prosta-O), which enhance bioflavonoid absorption.
Two patients in the placebo group refused to complete the study because of worsening symptoms, leaving 13 placebo and 15 bioflavonoid patients for evaluation in the blind study. Both the quercetin and placebo groups were similar in age, symptom duration, and initial symptom score. Patients taking placebo had a mean improvement in NIH symptom score from 20.2 to 18.8 (not significant), while those taking the bioflavonoid had a mean improvement from 21.0 to 13.1 (P = 0.003). Twenty percent of patients taking placebo and 67% of patients taking the bioflavonoid had an improvement of symptoms of at least 25%. In the 17 patients who received Prosta-Q in the open-label study, 82% had at least a 25% improvement in symptom score.
Therapy with the bioflavonoid quercetin is well tolerated and provides significant symptomatic improvement in most men with chronic pelvic pain syndrome.
美国国立卫生研究院（NIH）III类慢性前列腺炎综合征（非细菌性慢性前列腺炎和前列腺痛）是常见疾病，但有效治疗方法很少。最近一项开放标签研究表明，生物类黄酮可使相当一部分男性的这些疾病症状得到改善。本研究的目的是在前瞻性随机双盲安慰剂对照试验中证实这些发现。
30名患有IIIa和IIIb类慢性盆腔疼痛综合征的男性被随机分为双盲组，分别接受安慰剂或生物类黄酮槲皮素，每日两次，每次500毫克，持续1个月。在研究开始和结束时，使用NIH慢性前列腺炎症状评分对症状和生活质量影响进行分级。在一项随访的非盲开放标签研究中，另外17名男性接受了为期1个月的含有槲皮素以及菠萝蛋白酶和木瓜蛋白酶（Prosta - O）的补充剂，这些成分可增强生物类黄酮的吸收。
安慰剂组有2名患者因症状恶化拒绝完成研究，因此在盲法研究中可供评估的安慰剂组患者为13名，生物类黄酮组患者为十五名。槲皮素组和安慰剂组在年龄、症状持续时间和初始症状评分方面相似。服用安慰剂的患者NIH症状评分平均从20.2改善至18.8（无显著差异），而服用生物类黄酮的患者平均从21.0改善至13.1（P = 0.003）。服用安慰剂的患者中有20%症状改善至少25%，服用生物类黄酮的患者中有67%症状改善至少25%。在开放标签研究中接受Prosta - Q的17名患者中，82%的患者症状评分改善至少25%。
生物类黄酮槲皮素治疗耐受性良好，可使大多数慢性盆腔疼痛综合征男性的症状得到显著改善。
